Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab vs ipilimumab after complete resection of high‑risk stage IIIb/c or IV melanoma
2014-002351-26Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Adjuvant nivolumab with Adjuvant ipilimumab (2 arms). Primary endpoint: Recurrence-free survival. Started Jan 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-002351-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002351-26.